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Abstract
In dogs and cats an assessment of renal function is often needed, however, existing
methods including urine and plasma clearances are invasive, cumbersome and
time consuming. This pilot study evaluated the feasibility of a transcutaneous
glomerular filtration rate (GFR) measurement in dogs and cats. Additionally the
optimal dose and location for the transcutaneous measurement device were
investigated. Renal elimination of fluorescein-isothiocyanate-labelled sinistrin
(FITC-S) was measured transcutaneously for 4 hours. The procedures were
performed in awake, freely moving animals using escalating doses of FITC-S
(10 mg/kg, 30 mg/kg, 50 mg/kg) with a wash-out period of at least 24 h in between.
Multiple devices were placed on each animal. The resulting FITC-S disappearance
curves were visually assessed to determine the most suitable location and the
appropriate dose to reach an adequate transcutaneous peak signal for kinetic
analysis. In both species 30 mg/kg were adequate for kinetic calculation. The most
suitable place for the device was the lateral thoracic wall in dogs and the ventral
abdominal wall in cats, respectively. Transcutaneous FITC-S clearance was then
repeated using the optimal dose and location and in parallel with an additional
plasma sinistrin clearance. Plasma elimination half-lives [min] were 26, 31 and 35,
and corresponding transcutaneous elimination half-lives [min] were 26, 34 and 55,
respectively in the dogs. Plasma elimination half-lives [min] were 51, 60 and 61,
and corresponding transcutaneous elimination half-lives [min] were 75, 96 and 83,
respectively in the cats. In conclusion, transcutaneous FITC-S clearance is a
feasible method for the assessment of GFR in awake dogs and cats. It is
noninvasive, well tolerated and easy to perform even in a clinical setting with results
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being readily available. A dose of 30 mg/kg of FITC-S seems adequate for kinetic
assessment. Further studies are now needed to establish reference values and
evaluate transcutaneous renal clearance in various conditions.
Introduction
Determination of glomerular filtration rate (GFR) by means of plasma or urine
clearances of exogenous markers such as inulin (and its equivalent sinistrin),
iohexol, radionucleids or creatinine currently is the gold standard in assessing
renal function in pets. [1] Urinary clearance procedures are cumbersome and
harbor the risk of urinary tract infection owing to catheterization. Hence plasma
clearance methods such as the exogenous bolus sinistrin, [2] creatinine, [3] or
iohexol clearance, [4] are used in clinical settings. Repeated blood sampling after
injection of the respective marker is necessary, although protocols for limited
sampling strategies are available. [3,5,6] Another approach to determine GFR is to
measure the elimination of a fluorescent marker transcutaneously. These
procedures showed reliable results in rats and mice and newly developed devices
make it even possible to measure GFR in conscious animals. [7–11] The
transcutaneous approach to measure GFR has not yet been reported in larger
animals such as dogs and cats for veterinary use or as model for human patients. A
prospective study was designed to test the feasibility of a transcutaneous
assessment of renal function using FITC-S kinetics. The aims of the study were
threefold: to find the appropriate dose of FITC-S and the optimal position for the
optical device in dogs and cats and to see how the transcutaneously measured




Three healthy research dogs (female, 2–3 years, 7–9 kg) and three healthy research
cats (male, 2 years, 5 kg) were used for the procedures. The study was approved by
the state ethics and welfare committee Hessia (number 24/2013). The animals
were deemed healthy based on physical exam, complete blood count,
biochemistry profile, and urinalysis.
Experimental design
The study was separated into two parts. First the appropriate location of the
devices for transcutaneous measurement as well as the ideal dose of FITC-sinistrin
had to be determined. Therefore, the devices for the transcutaneous measurement
were placed at four different locations on each animal: antebrachium, metatarsus,
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lateral thoracic wall, and ventrolateral abdomen. Each animal received escalating
doses (10 mg/kg, 30 mg/kg, 50 mg/kg) of FITC-sinistrin at least 24 hours apart.
For the FITC-sinistrin solution the commercially available GFR marker Inutest,
containing the pharmacological active ingredient sinistrin (Fresenius Kabi, Linz,
Austria), was labeled with FITC as described previously [12,13].
A previously described protocol and device for transcutaneous measurement of
FITC-S clearance in rats was used in dogs and cats. [10] The devices (NIC-Kidney;
Mannheim Pharma & Diagnostics GmbH, Mannheim, Germany) are built up
from 2 light-emitting diodes with an emission maximum of about 480 nm and a
photodiode, which detects the light at 520 nm. After amplification and
digitalization the data are transferred to a computer program to determine the
kinetic parameters.
An area of 363 cm at the chosen locations was shaved and cleaned. For the
devices at the antebrachium and metatarsus the leg was circumferentially clipped.
The devices were attached to the skin (Fig. 1) using a sticky patch (Lohmann
GmbH & Co. KG, Neuwied, Germany) and fixed by a light bandage, insuring that
no pressure was applied on the device. After placement of the devices FITC-
sinistrin was injected at the respective dose as a bolus via an intravenous catheter
and the measurement was continued for 4 hours. During this time the animals
were allowed to move freely in an examination room.
The resulting transcutaneous disappearance curves were visually assessed to
determine the most suitable location (minimal artifacts, acceptable background
noise) and the appropriate dose to reach an adequate transcutaneous peak signal
for kinetic analysis. Afterwards the transcutaneous measurement of renal function
using the determined ideal dose of FITC-sinistrin and location of the device was
performed in parallel with a serum sinistrin clearance as described previously
[2,14].
Briefly, sinistrin was injected as a bolus intravenously immediately after the
FITC-sinistrin was administered. To reach a dose of 3000 mg/m2 the amount of
FITC-sinistrin was subtracted from the total dose and only the remainder injected.
Blood samples were taken through a separate venous access at the following time
points: 3, 10, 20, 40, 80, 120, and 180 minutes. The exact time points were noted
for clearance calculations.
Sinistrin in serum samples as well as the FITC-S solution were analyzed at a
commercial laboratory (Alomed, Radolfzell, Germany) as described previously.
[2,14] Analysis of the FITC-S solution was necessary to determine the exact dose
of sinistrin administered to allow for kinetic calculations. Plasma sinistrin
clearance and plasma half-life were calculated using a 2–compartment model with
a freely available pharmacokinetic calculator. [15] Transcutaneous half-life was
calculated from the single exponential slope of the transcutaneous disappearance
and its rate constant (m) curve via the formula ln(2)/m (one compartment
model).
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Results
All procedures were well tolerated in all animals and no side effects were noted.
In dogs the lateral thoracic wall was most appropriate for placement of the
devices as there were the least motion artifacts. An example of the different
localizations and the resulting transcutaneous disappearance curves in one dog is
shown in Fig. 2. In cats the curves obtained at the ventrolateral abdomen and
thoracic wall were of equivalent quality. However, instrumentalization (clipping,
attachment of the device) was easier to perform at the abdominal wall. Therefore,
the subsequent study was performed with the device attached at the ventrolateral
abdomen in cats and the thoracic wall in dogs. The dose of 30 mg/kg was deemed
adequate based on peak fluorescence and area under the curve in both species.
Additionally there was evidence of quenching (extinction of the transcutaneous
signal owing to a high optical density from a too high dose of FITC-S) in all three
cats using a dose of 50 mg/kg. An example of the resulting transcutaneous
disappearance curves using the three different dosages in one cat is shown in
Fig. 3. Transcutaneous disappearance curves of all animals using 30 mg/kg FITC-
S are shown in Fig. 4. The fitting of the transcutaneous elimination curve was
excellent with a r2.0.94 in all animals.
Plasma sinistrin data, clearances and half-lives, as well as transcutaneous half-
lives are presented in Tables 1 & 2.
Figure 1. The miniaturized device is placed on a clipped area on the ventral abdomen of a beagle dog
and attached using a sticky patch.
doi:10.1371/journal.pone.0111734.g001
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Discussion
This study demonstrates that the transcutaneous assessment of FITC-S clearance
is feasible in awake dogs and cats. This method has the potential to estimate GFR
in these species. It is minimally invasive as only an intravenous injection is
Figure 2. Transcutaneous disappearance curves of fluorescein-isothiocyanate-labelled sinistrin in a
dog with the device placed on the four different locations (A – hindlimb, B – forelimb, C – ventral
abdomen, D – lateral thorax). The x-axis represents time, the y-axis represents the relative transcutaneous
fluorescence. Note that there are minimal artifacts in curve D.
doi:10.1371/journal.pone.0111734.g002
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needed, but no further blood sampling is necessary. This allows for repeated
measurement of GFR even in very small or anemic patients. Another advantage is
that the results are readily available.
Figure 3. Transcutaneous disappearance curves of a cat using three different dosages of fluorescein-
isothiocyanate-labelled sinistrin (A: 10 mg/kg, B: 30 mg/kg, C: 50 mg/kg). The x-axis represents time,
the y-axis represents the relative transcutaneous fluorescence. The dose of 30 mg/kg (B) results in an
adequate peak concentration.
doi:10.1371/journal.pone.0111734.g003
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Our results show that there is considerable variation of half-life when using
plasma or transcutaneously derived data. This is especially true for cats and the
reason for this is unclear. The normal range or reference interval calculated for
different methods of GFR assessment vary considerably. [16] Therefore results
obtained by using one method cannot be directly compared to results derived
from another method. [1] Establishment of a reference interval using healthy
animals with normal renal function and animals with acute and chronic kidney
disease is therefore necessary before measuring GFR transcutaneously.
The locations for the placement of the device we found most suitable for
analysis are areas which need to be clipped in veterinary medicine for a variety of
reasons e.g. abdominal ultrasound, echocardiography, or placement of ECG
patches. Therefore no additional clipping is needed.
The determination of half-life or the rate constant m as surrogate for renal
function is not new in the field of veterinary medicine. Usually GFR is factored to
body weight or body surface area. [1] However, standardization to extracellular
fluid volume (ECFV) may be a more physiologic approach. The rate constant m of
the single exponential slope of the disappearance curve is a close estimate of GFR/
ECFV in humans and dogs and is converted to half-life via the simple equation
ln(2)/m [17–19].
Figure 4. Transcutaneous disappearance curves of fluorescein-isothiocyanate-labelled sinistrin in
three dogs (A–C) and three cats (D–F) using a dose of 30 mg/kg.
doi:10.1371/journal.pone.0111734.g004
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Determination of GFR/ECFV via plasma clearance of radio-isotopes and by an
external radiation detector has been previously performed in dogs. However,
considering radiation safety, this technique is not widely used. [19] Unfortunately
the authors do not report absolute values for mmaking a direct comparison of the
two studies impossible. Although one has to consider that the use of a one
compartment model for estimating GFR is not ideal and might overestimate renal
clearance especially in individuals with normal renal function [1,20], it is the only
method which can be used when assessing transcutaneously derived data [9].
To compare the transcutaneously measured clearance with the existing
literature or if the conventional indexing to body surface area or body weight is
required, clearance can be calculated from half-life using a species specific
conversion factor as it has been shown for rats. [9] As this was a study of
feasibility, only a small number of animals were included, rendering the
calculation of such a formula impossible.
The transcutaneous device is lightweight and all animals tolerated the
measurement well. Especially for cats this is a very attractive way of assessing GFR
Table 1. Plasma inulin data in all animals studied.
Sinistrin (mg/l)
Time (min) Dog 1 Dog 2 Dog 3 Cat 1 Cat 2 Cat 3
3 1126 1282 1195 2088 2045 1611
10 540 638 573 1153 1022 920
20 347 416 361 789 732 671
40 191 241 194 573 532 477
80 80 117 74 350 344 313
120 37 64 39 233 228 198
180 19 48 10 127 117 106
doi:10.1371/journal.pone.0111734.t001
Table 2. Results of serum sinistrin and transcutaneous fluorescein-isothiocyanate-labelled sinistrin clearance in all animals studied.
Parameter Dog 1 Dog 2 Dog 3 Cat 1 Cat 2 Cat 3
Body Weight (kg) 8.5 9.1 7.0 5.2 4.5 5.0
Body Surface Area (m2) 0.42 0.44 0.37 0.29 0.27 0.29
Serum Sinistrin Clearance (ml/min) 43.7 34.2 38.2 9.9 9.9 13.7
Serum Sinistrin Clearance (ml/min/kg) 5.0 3.8 5.5 1.9 2.2 2.7
Serum Sinistrin Clearance (ml/min/m2) 101.8 77.7 103.1 33.9 36.3 47.1
Serum Sinistrin half life (min) 32 35 28 61 60 51
Transcutaneous FITC-S half life (min) 34 55 26 83 96 75
k10 (min
21) 0.06 0.09 0.08 0.03 0.04 0.03
k12 (min
21) 0.08 0.18 0.15 0.09 0.13 0.10
k21 (min
21) 0.07 0.07 0.10 0.06 0.07 0.08
Vss (ml) 1578 1355 1256 762 755 907
(FITC-S5fluorescein-isothiocyanate-labelled sinistrin, k5transfer rate between compartments, Vss5Volume of distribution under steady state conditions).
doi:10.1371/journal.pone.0111734.t002
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as restriction is only needed to inject the marker substance intravenously and fix
the device. No further manipulation is necessary. Moreover, results of the GFR
measurement are readily available to the clinician.
Skin blood flow is independent of skin thickness, however, both parameters
vary between species. Additionally, these parameters vary in different body areas
within an animal. [21] Therefore caution is warranted if comparisons are drawn
in future studies as only data from the same location in the same species should be
compared. Furthermore, the use on pigmented or inflamed skin may lead to
decreased or increased signal amplitude, respectively. Further studies are necessary
to evaluate how skin condition and pigmentation may influence the transcuta-
neous measurement of FITC-S.
In conclusion, transcutaneous FITC-S clearance is a feasible and non-invasive
method for assessment of GFR in awake dogs and cats. Further studies are
necessary to establish reference values for the transcutaneous half-life of FITC-S in
healthy animals and animals with varying degree of renal disease.
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